Type II CRISPR/Cas9 approach in the oncological therapy
Abstract CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) is a prokaryotic adaptable immune mechanism used by many bacteria and archaea to protect themselves from foreign nucleic acids. This complex system can recognize and cut non-self DNA in order to provide the prokaryotic organ...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2017-06-01
|
| Series: | Journal of Experimental & Clinical Cancer Research |
| Subjects: | |
| Online Access: | http://link.springer.com/article/10.1186/s13046-017-0550-0 |
| _version_ | 1818257997770522624 |
|---|---|
| author | A. Biagioni A. Chillà E. Andreucci A. Laurenzana F. Margheri S. Peppicelli M. Del Rosso G. Fibbi |
| author_facet | A. Biagioni A. Chillà E. Andreucci A. Laurenzana F. Margheri S. Peppicelli M. Del Rosso G. Fibbi |
| author_sort | A. Biagioni |
| collection | DOAJ |
| description | Abstract CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) is a prokaryotic adaptable immune mechanism used by many bacteria and archaea to protect themselves from foreign nucleic acids. This complex system can recognize and cut non-self DNA in order to provide the prokaryotic organisms a strong defense against foreign viral or plasmid attacks and make the cell immune from further assaults. Today, it has been adapted to be used in vitro and in vivo in eukaryotic cells to perform a complete and highly selective gene knockout or a specific gene editing. The ease of use and the low cost are only two features that have made it very popular among the scientific community and the possibility to be used as a clinical treatment in several genetic derived pathologies has rapidly spread its fame worldwide. However, CRISPR is still not fully understood and many efforts need to be done in order to make it a real power tool for the human clinical treatment especially for oncological patients. Indeed, since cancer originates from non-lethal genetic disorders, CRISPR discovery fuels the hope to strike tumors on their roots. More than 4000 papers regarding CRISPR were published in the last ten years and only few of them take in count the possible applications in oncology. The purpose of this review is to clarify many problematics on the CRISPR usage and highlight its potential in oncological therapy. |
| first_indexed | 2024-12-12T17:52:33Z |
| format | Article |
| id | doaj.art-0a5005e5eaed4d0398e30466192946c2 |
| institution | Directory Open Access Journal |
| issn | 1756-9966 |
| language | English |
| last_indexed | 2024-12-12T17:52:33Z |
| publishDate | 2017-06-01 |
| publisher | BMC |
| record_format | Article |
| series | Journal of Experimental & Clinical Cancer Research |
| spelling | doaj.art-0a5005e5eaed4d0398e30466192946c22022-12-22T00:16:47ZengBMCJournal of Experimental & Clinical Cancer Research1756-99662017-06-013611810.1186/s13046-017-0550-0Type II CRISPR/Cas9 approach in the oncological therapyA. Biagioni0A. Chillà1E. Andreucci2A. Laurenzana3F. Margheri4S. Peppicelli5M. Del Rosso6G. Fibbi7Department of Experimental and Clinical Biomedical Sciences, Section of Experimental Pathology and Oncology, University of FlorenceDepartment of Experimental and Clinical Biomedical Sciences, Section of Experimental Pathology and Oncology, University of FlorenceDepartment of Experimental and Clinical Biomedical Sciences, Section of Experimental Pathology and Oncology, University of FlorenceDepartment of Experimental and Clinical Biomedical Sciences, Section of Experimental Pathology and Oncology, University of FlorenceDepartment of Experimental and Clinical Biomedical Sciences, Section of Experimental Pathology and Oncology, University of FlorenceDepartment of Experimental and Clinical Biomedical Sciences, Section of Experimental Pathology and Oncology, University of FlorenceDepartment of Experimental and Clinical Biomedical Sciences, Section of Experimental Pathology and Oncology, University of FlorenceDepartment of Experimental and Clinical Biomedical Sciences, Section of Experimental Pathology and Oncology, University of FlorenceAbstract CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) is a prokaryotic adaptable immune mechanism used by many bacteria and archaea to protect themselves from foreign nucleic acids. This complex system can recognize and cut non-self DNA in order to provide the prokaryotic organisms a strong defense against foreign viral or plasmid attacks and make the cell immune from further assaults. Today, it has been adapted to be used in vitro and in vivo in eukaryotic cells to perform a complete and highly selective gene knockout or a specific gene editing. The ease of use and the low cost are only two features that have made it very popular among the scientific community and the possibility to be used as a clinical treatment in several genetic derived pathologies has rapidly spread its fame worldwide. However, CRISPR is still not fully understood and many efforts need to be done in order to make it a real power tool for the human clinical treatment especially for oncological patients. Indeed, since cancer originates from non-lethal genetic disorders, CRISPR discovery fuels the hope to strike tumors on their roots. More than 4000 papers regarding CRISPR were published in the last ten years and only few of them take in count the possible applications in oncology. The purpose of this review is to clarify many problematics on the CRISPR usage and highlight its potential in oncological therapy.http://link.springer.com/article/10.1186/s13046-017-0550-0CRISPRGene therapyGene deliveryGenetic engineeringImmune therapyOncology |
| spellingShingle | A. Biagioni A. Chillà E. Andreucci A. Laurenzana F. Margheri S. Peppicelli M. Del Rosso G. Fibbi Type II CRISPR/Cas9 approach in the oncological therapy Journal of Experimental & Clinical Cancer Research CRISPR Gene therapy Gene delivery Genetic engineering Immune therapy Oncology |
| title | Type II CRISPR/Cas9 approach in the oncological therapy |
| title_full | Type II CRISPR/Cas9 approach in the oncological therapy |
| title_fullStr | Type II CRISPR/Cas9 approach in the oncological therapy |
| title_full_unstemmed | Type II CRISPR/Cas9 approach in the oncological therapy |
| title_short | Type II CRISPR/Cas9 approach in the oncological therapy |
| title_sort | type ii crispr cas9 approach in the oncological therapy |
| topic | CRISPR Gene therapy Gene delivery Genetic engineering Immune therapy Oncology |
| url | http://link.springer.com/article/10.1186/s13046-017-0550-0 |
| work_keys_str_mv | AT abiagioni typeiicrisprcas9approachintheoncologicaltherapy AT achilla typeiicrisprcas9approachintheoncologicaltherapy AT eandreucci typeiicrisprcas9approachintheoncologicaltherapy AT alaurenzana typeiicrisprcas9approachintheoncologicaltherapy AT fmargheri typeiicrisprcas9approachintheoncologicaltherapy AT speppicelli typeiicrisprcas9approachintheoncologicaltherapy AT mdelrosso typeiicrisprcas9approachintheoncologicaltherapy AT gfibbi typeiicrisprcas9approachintheoncologicaltherapy |